CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

2024.12.03
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department of Hematology at Xinqiao Hospital , Army Medical University shared key insights on chronic graft-versus-host disease (cGVHD).
How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

2024.12.03
Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences delivered a compelling presentation on treating severe aplastic anemia. In an interview with Hematology Frontier, Prof. Zhang shared insights into managing refractory aplastic anemia and the latest treatment advancements.
2024 Great Wall Hematology Forum丨Prof. Wenming Chen: Integrating Fundamentals and Clinical Practice to Foster Young Talent

2024 Great Wall Hematology Forum丨Prof. Wenming Chen: Integrating Fundamentals and Clinical Practice to Foster Young Talent

2024.12.03
On November 15–16, 2024, the "Annual Meeting of the Hematology Committee of the Chinese Medical Education Association—Great Wall Hematology Forum" was successfully held in Beijing. This conference brought together leading experts in hematology to discuss advancements in the diagnosis and treatment of hematological diseases, delve into the latest research findings, and explore the future direction of the field. Hematology Frontier had the honor of interviewing Professor Wenming Chen, Chair of the Hematology Committee and Director of the Hematology Department at Beijing Chaoyang Hospital, who shared highlights of the forum, significant achievements in China’s hematology research, and his insights into nurturing young scholars.
SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

2024.12.03
The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier interviewed several prominent members of the advisory board who participated in the voting, including Prof. Yiding Chen, Prof. Hengyu Li, Prof. Man Li, Prof. Shu Liu, Prof. Yongsheng Wang, and Prof. Jian Zhang, to provide insights into the potential updates in the 2025 edition.
Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients

Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients

2024.12.02
Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch the Zhōng & Huì Insights clinical progress series. Through in-depth analyses of high-quality clinical research in lung cancer, the series aims to elevate clinical practice standards. In this 24th installment, the professors discuss the results of the study titled "Efficacy and Safety of Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients," published in The Lancet Respiratory Medicine by Dr. Baohui Han as the first author.
Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

2024.12.02
Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.
The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

2024.12.02
Urothelial carcinoma (UC) is one of the most common malignant tumors of the urinary system, encompassing bladder cancer, renal pelvic cancer, and ureteral cancer. Radiotherapy, as a critical treatment modality for tumors, has gained prominence in the comprehensive treatment of UC, offering hope for improved survival outcomes. During the 8th West China Urologic Oncology Academic Conference held in Chengdu, Oncology Frontier invited Dr. Hongzhen Li from Peking University First Hospital to share the latest advancements in radiotherapy for UC.